Name:
Dr Essam Kerwash FBPhS
Organisation:
Medicines and Health products Regulatory Agnecy
Year elected:
2023
Primary professional setting:
Government
Essam Ghazaly Kerwash, MB BCh, MSc, MD/PhD, FHEA, is a leading senior clinical pharmacology assessor at the MHRA. Essam Obtained his PhD in Clinical Pharmacology from University of London studying the interindividual variabilities in response to anti-cancer drugs. He received post-doctoral training at Barts Cancer Institute where his research was focused on the discovery of novel biomarkers that can predict activity/toxicity of the cytotoxic agents using Omics approach. He supported the drug development of new generation of anti-metabolites with improved efficacy and pharmacokinetics. At the MHRA, he assessed the clinical pharmacology aspects of license applications to support early patient access to number of innovative medicines. Essam is recognised for expertise in cancer pharmacology, biosimilars, population and physiologically based modelling where he contributed to national and ICH guidelines such as ICH M15 guideline. He is co-leading an active research program investigating the use of modelling to support optimisation of the dose for medicines commonly used during pregnancy and lactation. Essam received merit awards such as Conquer Cancer the ASCO Foundation merit award.